- Home
- AAMI vs SRPT Comparison
AAMI vs SRPT Comparison
Compare AAMI & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AAMI
- SRPT
- Stock Information
- Founded
- AAMI 1980
- SRPT 1980
- Country
- AAMI United States
- SRPT United States
- Employees
- AAMI N/A
- SRPT N/A
- Industry
- AAMI Investment Managers
- SRPT Biotechnology: Pharmaceutical Preparations
- Sector
- AAMI Finance
- SRPT Health Care
- Exchange
- AAMI Nasdaq
- SRPT Nasdaq
- Market Cap
- AAMI 1.6B
- SRPT 1.9B
- IPO Year
- AAMI N/A
- SRPT 1997
- Fundamental
- Price
- AAMI $44.19
- SRPT $23.72
- Analyst Decision
- AAMI Hold
- SRPT Hold
- Analyst Count
- AAMI 3
- SRPT 31
- Target Price
- AAMI $39.67
- SRPT $40.61
- AVG Volume (30 Days)
- AAMI 280.0K
- SRPT 6.3M
- Earning Date
- AAMI 10-30-2025
- SRPT 11-05-2025
- Dividend Yield
- AAMI 0.09%
- SRPT N/A
- EPS Growth
- AAMI 43.58
- SRPT N/A
- EPS
- AAMI 2.41
- SRPT N/A
- Revenue
- AAMI $538,200,000.00
- SRPT $2,481,531,000.00
- Revenue This Year
- AAMI $21.37
- SRPT $9.41
- Revenue Next Year
- AAMI $16.37
- SRPT N/A
- P/E Ratio
- AAMI $18.50
- SRPT N/A
- Revenue Growth
- AAMI 18.76
- SRPT 64.89
- 52 Week Low
- AAMI $22.60
- SRPT $10.42
- 52 Week High
- AAMI $51.65
- SRPT $138.81
- Technical
- Relative Strength Index (RSI)
- AAMI 39.50
- SRPT 71.18
- Support Level
- AAMI $46.88
- SRPT $17.57
- Resistance Level
- AAMI $47.45
- SRPT $23.42
- Average True Range (ATR)
- AAMI 1.52
- SRPT 1.36
- MACD
- AAMI -0.63
- SRPT 0.61
- Stochastic Oscillator
- AAMI 3.78
- SRPT 77.97
About AAMI Acadian Asset Management Inc. Common Stock
Acadian Asset Management Inc is a holding company that operates a systematic investment management business through its subsidiary, that offers institutional investors across the globe access to a diversified array of systematic investment strategies designed to meet a range of risk and return objectives.
About SRPT Sarepta Therapeutics Inc. (DE)
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.